PMID- 31501276
OWN - NLM
STAT- MEDLINE
DCOM- 20200225
LR  - 20210816
IS  - 1098-5549 (Electronic)
IS  - 0270-7306 (Print)
IS  - 0270-7306 (Linking)
VI  - 39
IP  - 23
DP  - 2019 Dec 1
TI  - ESR1-Stabilizing Long Noncoding RNA TMPO-AS1 Promotes Hormone-Refractory Breast 
      Cancer Progression.
LID - 10.1128/MCB.00261-19 [doi]
LID - e00261-19
AB  - Acquired endocrine therapy resistance is a significant clinical problem for 
      breast cancer patients. In recent years, increasing attention has been paid to 
      long noncoding RNA (lncRNA) as a critical modulator for cancer progression. Based 
      on RNA-sequencing data of breast invasive carcinomas in The Cancer Genome Atlas 
      database, we identified thymopoietin antisense transcript 1 (TMPO-AS1) as a 
      functional lncRNA that significantly correlates with proliferative biomarkers. 
      TMPO-AS1 positivity analyzed by in situ hybridization significantly correlates 
      with poor prognosis of breast cancer patients. TMPO-AS1 expression was 
      upregulated in endocrine therapy-resistant MCF-7 cells compared with levels in 
      parental cells and was estrogen inducible. Gain and loss of TMPO-AS1 experiments 
      showed that TMPO-AS1 promotes the proliferation and viability of estrogen 
      receptor (ER)-positive breast cancer cells in vitro and in vivo Global expression 
      analysis using a microarray demonstrated that TMPO-AS1 is closely associated with 
      the estrogen signaling pathway. TMPO-AS1 could positively regulate estrogen 
      receptor 1 (ESR1) mRNA expression by stabilizing ESR1 mRNA through interaction 
      with ESR1 mRNA. Enhanced expression of ESR1 mRNA by TMPO-AS1 could play a 
      critical role in the proliferation of ER-positive breast cancer. Our findings 
      provide a new insight into the understanding of molecular mechanisms underlying 
      hormone-dependent breast cancer progression and endocrine resistance.
CI  - Copyright (c) 2019 American Society for Microbiology.
FAU - Mitobe, Yuichi
AU  - Mitobe Y
AD  - Division of Gene Regulation and Signal Transduction, Research Center for Genomic 
      Medicine, Saitama Medical University, Saitama, Japan.
FAU - Ikeda, Kazuhiro
AU  - Ikeda K
AD  - Division of Gene Regulation and Signal Transduction, Research Center for Genomic 
      Medicine, Saitama Medical University, Saitama, Japan.
FAU - Suzuki, Takashi
AU  - Suzuki T
AD  - Department of Pathology and Histotechnology, Tohoku University Graduate School of 
      Medicine, Miyagi, Japan.
FAU - Takagi, Kiyoshi
AU  - Takagi K
AD  - Department of Pathology and Histotechnology, Tohoku University Graduate School of 
      Medicine, Miyagi, Japan.
FAU - Kawabata, Hidetaka
AU  - Kawabata H
AD  - Department of Breast and Endocrine Surgery, Toranomon Hospital, Tokyo, Japan.
FAU - Horie-Inoue, Kuniko
AU  - Horie-Inoue K
AD  - Division of Gene Regulation and Signal Transduction, Research Center for Genomic 
      Medicine, Saitama Medical University, Saitama, Japan.
FAU - Inoue, Satoshi
AU  - Inoue S
AD  - Division of Gene Regulation and Signal Transduction, Research Center for Genomic 
      Medicine, Saitama Medical University, Saitama, Japan sinoue@tmig.or.jp.
AD  - Department of Systems Aging Science and Medicine, Tokyo Metropolitan Institute of 
      Gerontology, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191112
PL  - United States
TA  - Mol Cell Biol
JT  - Molecular and cellular biology
JID - 8109087
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (ESR1 protein, human)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Nuclear Proteins)
RN  - 0 (RNA, Antisense)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA, Messenger)
RN  - 0 (Thymopoietins)
RN  - 157298-12-9 (TMPO protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/physiology
MH  - Cell Survival/physiology
MH  - Disease Progression
MH  - Estrogen Receptor alpha/*genetics/metabolism
MH  - Female
MH  - Gene Knockdown Techniques
MH  - Humans
MH  - MCF-7 Cells
MH  - Middle Aged
MH  - Nuclear Proteins/*genetics/metabolism
MH  - Prognosis
MH  - RNA, Antisense/*genetics/metabolism
MH  - RNA, Long Noncoding/genetics
MH  - RNA, Messenger/genetics/metabolism
MH  - Signal Transduction
MH  - Thymopoietins/*genetics/metabolism
MH  - Transcriptional Activation
PMC - PMC6851347
OTO - NOTNLM
OT  - RNA stability
OT  - breast cancer
OT  - estrogen
OT  - long noncoding RNA
EDAT- 2019/09/11 06:00
MHDA- 2020/02/26 06:00
PMCR- 2020/05/12
CRDT- 2019/09/11 06:00
PHST- 2019/06/12 00:00 [received]
PHST- 2019/09/04 00:00 [accepted]
PHST- 2019/09/11 06:00 [pubmed]
PHST- 2020/02/26 06:00 [medline]
PHST- 2019/09/11 06:00 [entrez]
PHST- 2020/05/12 00:00 [pmc-release]
AID - MCB.00261-19 [pii]
AID - 00261-19 [pii]
AID - 10.1128/MCB.00261-19 [doi]
PST - epublish
SO  - Mol Cell Biol. 2019 Nov 12;39(23):e00261-19. doi: 10.1128/MCB.00261-19. Print 
      2019 Dec 1.